한글목차

생물학적 제제 수탁 개발 동향 및 전망

세계 생물학적 제제 수탁 개발 시장의 미래는 암, 면역질환, 심혈관질환, 혈액질환 시장에 기회가 있어 유망합니다. 세계 생물학적 제제 수탁 개발 시장은 2024년부터 2030년까지 11.5%의 CAGR로 2030년까지 약 409억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 제약 회사의 의약품 개발 절차 증가, 첨단 기술 채택 확대, 개발 도상국의 임상시험에 유리한 환경입니다.

• Lucintel은 포유류 세포의 단백질 발현에 대한 포유류 세포의 채택이 증가하고 있으며, 적절한 번역 후 변형이 이루어진 포유류 단백질을 개발하면 네이티브 구조를 얻을 수 있다는 큰 이점이 있기 때문에 포유류는 예측 기간 동안 소스 카테고리에서 큰 부문으로 남을 것으로 예상하고 있습니다.
• 이 질환 적응증 중 암 분야는 치료에 대한 수요 증가로 인해 R&D 및 아웃소싱에 대한 투자가 증가함에 따라 가장 큰 부문으로 남을 것으로 보입니다.
• 지역별로는 북미가 R&D 투자 증가, 임상시험 수요 증가, 주요 기업의 존재로 인해 예측 기간 동안 가장 큰 지역으로 남을 것으로 보입니다.

생물학적 제제 수탁 개발의 전략적 성장 기회

기술의 발전, 시장의 새로운 기대, 정부의 지원은 생물학적 제제 수탁 개발 업계에 전략적 성장 기회를 제공합니다. 이러한 기회를 파악하여 성장과 경쟁력 강화를 위해 활용해야 합니다.

• 신흥 시장의 출현 : 새로운 지역으로의 진출은 업계 관계자의 위험을 줄이는 동시에 새로운 수익원을 창출할 수 있습니다. 이들 지역에서는 국제 시장 진출과 생명공학 산업의 발전과 함께 생물학적 제제 개발 위탁 서비스에 대한 관심이 높아지고 있습니다.
• 세포 및 유전자 치료 서비스의 발전 : 새로운 세포 및 유전자 치료의 등장으로 개발 서비스에 대한 수요가 증가하고 있으며, CDO는 이러한 역량에 투자함으로써 이러한 전문 서비스를 원하는 고객의 요구를 충족시킬 수 있습니다.
• 경제적 관점 : 다양한 지역의 경제적 권한 부여는 생명공학의 발전을 촉진할 것입니다. 많은 고객들이 단기적인 투자 회수에 얽매이지 않고 장기적인 이익을 추구할 수 있게 되었습니다.
• 첨단 기술 통합 : 기업 전체의 전략은 첨단 기술 개발 및 통합에 긍정적인 영향을 미치며, CDO는 시장에서의 지위를 유지하고 성장시키기 위해 현재 서비스 내용을 공동 개발해야 합니다.
• 최첨단 제조 기술 활용 : 혁신적인 제조 기술은 생산성을 높이고 제조 비용을 절감하며, CDO는 이러한 기술을 채택함으로써 더 나은 서비스를 제공하고 확장 가능하고 저렴한 생물학적 제제 제조에 대한 수요 증가에 대응할 수 있습니다.
• 디지털 분석 및 AI 통합 채택 : AI와 고급 분석은 의사결정과 프로세스 최적화를 개선합니다. 이러한 기술은 업무 효율성을 높이고 개발 시간을 단축하여 경쟁력을 강화합니다.
• 국제 파트너십에 참여 : 전략적 세계 파트너십은 원하는 시장에 대한 접근을 제공하고, 자원을 모으고, 사내 전문성을 활용할 수 있도록 도와줍니다. 협업은 혁신을 촉진하고, 국제적인 확장을 촉진하며, 시장에서의 입지를 강화할 수 있습니다.

신흥국 시장 진출, 세포 및 유전자 치료 서비스 고도화, 혁신적인 제조 기술 도입, AI 통합, 세계 파트너십 형성 등 전략적 성장 기회가 생물학적 제제 수탁 개발 시장을 형성하고 있습니다. 이러한 기회를 포착하는 것이 성장을 촉진하고 경쟁력을 향상시키며 산업을 구축할 수 있습니다.

생물학적 제제 수탁 개발 시장의 시장 촉진요인 및 과제

바이오의약품 위탁 개발 시장은 기술 발전, 정치적 지원, 민간 부문의 참여 등 다양한 요인에 의해 주도되고 있습니다. 이러한 요인은 수요 증가, 투자 유치, 효과적인 전략 수립에 필수적입니다.

생물학적 제제 수탁 개발 시장을 이끄는 요인은 다음과 같습니다.

• 기술 발전 : 기술 발전 : 기술 발전은 생물학적 제제의 생산 효율과 생산능력을 향상시킵니다. 연속 생산 및 공정 자동화와 같은 신기술은 안전성을 높이고 비용을 절감하여 시장 성장을 촉진할 것입니다.
• 생물학적 제제에 대한 수요 증가 : 전문 개발 업무 위탁에 대한 수요 증가는 생물학적 제제에 대한 수요 증가가 원동력이 되고 있습니다. 새로운 치료법이 등장함에 따라 CDO는 이러한 복잡한 치료법의 개발 및 생산을 지원하기 위해 업무를 조정해야 합니다.
• 규제 당국의 우호적인 경영 환경 : 우호적인 규제 환경은 승인 절차를 가속화하고 진입 장벽을 낮춥니다. 이러한 규제 조항은 투자자를 유치하고 새로운 생물학적 치료제의 출현을 촉진합니다.
• 비용 효율성과 아웃소싱 트렌드 : CDO에 업무를 위탁함으로써 기업은 핵심 업무에 집중하면서 비용을 절감할 수 있습니다. 이러한 추세는 CDO 서비스에 대한 수요를 증가시키고 시장 확대를 촉진할 것입니다.
• 연구 개발 투자 증가 : 연구 개발 투자 증가는 새로운 생물학적 제제의 신속한 개발로 이어집니다. 이 투자는 시장 성장을 촉진하고 CDO의 능력을 향상시킬 것입니다.

생물학적 제제 수탁 개발 시장의 과제는 다음과 같습니다.

• 규제의 복잡성 : 규제의 복잡성 : 규제의 복잡성은 개발 기간을 연장하고 비용을 증가시킬 수 있습니다. 기업은 감사 리소스를 확보하고, 컴플라이언스 정책의 변경 사항을 모니터링하고, 필요한 변경 사항을 확실히 이행해야 합니다.
• 높은 개발 비용 : 높은 개발 비용은 시장 진입을 제한하고 수익성에 영향을 미칩니다. 이 문제를 극복하기 위해서는 효과적인 비용 관리와 투자 전략이 필요합니다.
• 높은 경쟁 : 치열한 경쟁은 시장 점유율과 가격 설정에 영향을 미칩니다. CDO가 우위를 점하기 위해서는 기술 혁신, 양질의 업무, 우수한 고객 서비스를 통해 차별화를 꾀해야 합니다.

생물학적 제제 수탁 개발 시장의 촉진요인으로는 기술 발전, 바이오의약품 수요 증가, 규제 환경 개선, 운영 비용 절감, 연구개발 투자 증가 등이 있습니다. 그러나 성공적인 시장 진입을 위해서는 규제 장애물, 높은 개발 비용, 치열한 경쟁과 같은 과제를 극복해야 합니다. 이러한 촉진요인과 도전의 균형을 맞추는 것이 업계의 성장과 혁신을 달성하는 열쇠입니다.

목차

제1장 주요 요약

제2장 세계의 생물학적 제제 수탁 개발 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 2018년부터 2030년까지 시장 동향과 예측 분석

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 생물학적 제제 수탁 개발 시장 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 생물학적 제제 수탁 개발 시장 : 공급원별
  • 미생물
  • 포유류
  • 기타
• 생물학적 제제 수탁 개발 시장 : 제품 서비스별
  • 세포주 개발
  • 프로세스 개발
  • 기타
• 별 세계의 생물학적 제제 수탁 개발 시장 : 질환 적응증별
  • 종양학
  • 면역질환
  • 심혈관질환
  • 혈액질환
  • 기타

제4장 2018년부터 2030년까지 지역별 시장 동향과 예측 분석

• 지역별 생물학적 제제 수탁 개발 시장
• 북미의 생물학적 제제 수탁 개발 시장
• 유럽의 생물학적 제제 수탁 개발 시장
• 아시아태평양의 생물학적 제제 수탁 개발 시장
• 기타 지역의 생물학적 제제 수탁 개발 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 업무 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 공급원별 : 세계의 생물학적 제제 수탁 개발 시장 성장 기회
  • 제품 서비스별 : 세계의 생물학적 제제 수탁 개발 시장 성장 기회
  • 질환 적응증별 : 세계의 생물학적 제제 수탁 개발 시장 성장 기회
  • 지역별 : 세계의 생물학적 제제 수탁 개발 시장 성장 기회
• 세계의 생물학적 제제 수탁 개발 시장 최신 동향
• 전략 분석
  • 신제품 개발
  • 세계의 생물학적 제제 수탁 개발 시장 능력 확대
  • 세계의 생물학적 제제 수탁 개발 시장 합병, 인수, 합작투자
  • 인증과 라이선싱

제7장 주요 기업 개요

• WuXi Biologics
• Abzena
• Fujifilm Diosynth Biotechnologies
• KBI Biopharma
• AGC Biologics
• Thermo Fisher Scientific
• Curia Global
• GenScript
• Bionova Scientific
• BioXcellence

영문목차

Biologics Contract Development Trends and Forecast

The future of the global biologics contract development market looks promising with opportunities in the oncology, immunological disorder, cardiovascular disorder, and hematological disorder markets. The global biologics contract development market is expected to reach an estimated $40.9 billion by 2030 with a CAGR of 11.5% from 2024 to 2030. The major drivers for this market are the rising number of drug development procedures by pharmaceutical companies, the growing adoption of advanced technologies, and a favorable environment for clinical trials in developing countries.

• Lucintel forecasts that, within the source category, mammalian will remain a larger segment over the forecast period due to the increasing adoption of mammalian cells for protein expression, which provides a major advantage by developing mammalian proteins with correct post-translational modifications that deliver a native structure.
• Within this disease indication category, oncology will remain the largest segment due to the growing demand for therapy, which encourages more investments in research and development and outsourcing.
• In terms of regions, North America will remain the largest region over the forecast period due to growing R&D investments, rising demand for clinical trials, and the presence of major players in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Biologics Contract Development Market

The biologics contract development market is consistent with the development of technology, regulatory changes, evolving relationships, and the booming population. These trends are changing the marketplace and affecting how contract development organizations and pharmaceutical companies operate.

• Adoption of Advanced Manufacturing Technologies: Advanced manufacturing technologies enhance the efficiency, scalability, and flexibility in the production of biologics. For instance, continuous manufacturing reduces the time required in the production process and significantly reduces operational costs. Modular systems help optimize production by quickly reconfiguring processes.
• Growth of Cell and Gene Therapy: The growing popularity of cell and gene therapies creates a need for specialized contract development services. Contract development organizations (CDOs) are establishing competence in this area to offer services that are specific to the complex and regulation-heavy processes involved in manufacturing advanced therapies.
• Integration of Artificial Intelligence and Data Analytics: AI and data analytics enhance the quality of decision-making, increase efficiency in R&D processes, and improve production. These technologies help develop biologics by enhancing predictive modeling, adopting significant process control methods, and facilitating the analysis of data to reduce lead time and improve outcomes.
• Increasing Focus on Regulatory Compliance: As legal regulations become more complex, compliance has become a focal point for contract development organizations. Emphasizing the fulfillment of legal requirements reduces risks, improves product standards, and accelerates biological approval processes.
• International Partnerships and Collaborations: Collaborations allow organizations to develop new territories, pool assets, and capitalize on synergistic skills. Cooperation between contract development organizations and biotechnology companies from different countries promotes innovation, shortens development timelines, and helps distribute products in various regions.

Emerging trends such as innovations in manufacturing technologies increases in cell and gene therapy, AI applications, pressure to adhere to regulatory measures, and international partnerships are revolutionizing the biologics contract development industry. These factors lead to innovation and increased efficiencies, and address the growing demand for biologics, positioning the industry for continued growth and transformation.

Recent Developments in the Biologics Contract Development Market

Recent progress in the biologics contract development market highlights trends in technological advancement, supportive regulations, and market expansion. Key developments include advancements in manufacturing processes, increased R&D funding, and regulations that support the market's growth and evolution.

• New Manufacturing Technologies: New manufacturing technologies offer efficient and scalable operations, reducing production costs and time. Continuous manufacturing eliminates nonproductive time by allowing production processes to be altered as needed and increases product uniformity. Modular systems improve adaptability and allow quick responses to changing production requirements.
• Broader Cell and Gene Therapy Services: The increasing production of cell and gene therapies has led to more contract development services for these therapies. CDOs are investing in specific technologies and professionals to manage complex regulatory requirements for these specialized facilities.
• AI and Data Analytics in Processes: AI and data analytics optimize drug development processes and enhance performance during manufacturing. These technologies provide advanced modeling, system controls, and real-time data analytics to improve efficiency and shorten development timelines.

Recent trends, including advancements in manufacturing technologies, enhanced cell and gene therapies, AI integration, regulatory improvements, and growing international alliances, are greatly influencing the biologics contract development market. These efficiencies lead to technological advancements and international expansion, driving growth in the industry.

Strategic Growth Opportunities for Biologics Contract Development Market

Technological improvements, new market expectations, and government support provide strategic growth opportunities in the biologics contract development industry. These opportunities should be identified and leveraged to enhance growth and competitiveness.

• Emergence of Emerging Markets: Expanding into new regions reduces risk for industry players while opening new revenue streams. These areas are increasingly inclined toward biologics contract development services as they enter international markets or develop the biotech industry.
• Development of Cell and Gene Therapy Services: The rise of new cell and gene therapies has created a demand for development services. As CDOs invest in these competencies, they empower themselves to meet the needs of clients seeking these specialized services.
• Economic Perspectives: Economic empowerment in different regions should enhance biotechnology development. Many clients are now able to look beyond the immediate return on investment and explore long-term benefits.
• Integration of Advanced Technologies: Overall company strategies positively impact the development and integration of advanced technologies. CDOs must co-develop current service offerings to maintain or grow their position in the market.
• Utilizing Cutting-Edge Manufacturing Practices: Innovative manufacturing technologies increase productivity and reduce production costs. CDOs can adopt these technologies to provide better offerings and meet the increasing demand for scalable and affordable biologics production.
• Adoption of Digital Analytics and AI Integration: AI and advanced analytics improve decision-making and process optimization. These technologies enhance competitiveness by increasing operational efficiency and reducing development time.
• Entering International Partnerships: Strategic global partnerships provide access to desirable markets, pool resources, and leverage in-house expertise. Collaborations foster innovation, encourage international expansion and strengthen market position.

Strategic growth opportunities such as expanding into emerging markets, advancing cell and gene therapy services, adopting innovative manufacturing technologies, integrating AI, and forming global partnerships are shaping the biologics contract development market. Capturing these opportunities will drive growth, improve competitiveness, and build the industry.

Biologics Contract Development Market Driver and Challenges

The biologics contract development market is driven by various factors, including technological advancements, political support, and private sector involvement. These factors are essential for increasing demand, attracting investment, and formulating effective strategies.

The factors driving the biologics contract development market include:

• Advances in Technology: Technological developments improve the efficiency and capacity of biologics production. New technologies, such as continuous manufacturing and process automation, enhance safety and reduce costs, thereby fostering market growth.
• Increased Demand for Biologics: The rising demand for specialized contract development services is driven by the growing need for biologics. As new therapies emerge, CDOs must adjust operations to support the development and production of these complex therapies.
• Favorable Operating Environment for Regulatory Agencies: Supportive regulatory environments accelerate the approval process and lower entry barriers. Such regulatory provisions attract investors and facilitate the emergence of novel biological therapies.
• Cost Efficiency and Outsourcing Trends: Outsourcing operations to CDOs allows companies to reduce expenses while focusing on core activities. This trend creates a growing need for CDO services, driving market expansion.
• Rising Investment in R&D: Increased investment in R&D leads to faster development of new biologics. This investment boosts market growth and improves the capabilities of CDOs.

Challenges in the biologics contract development market include:

• Regulatory Complexity: Regulatory complexity can extend development timelines and increase costs. Companies must secure auditing resources, monitor changes in compliance policies, and ensure necessary changes are implemented.
• High Development Costs: High development costs can limit market entry and affect profitability. Effective cost control and investment strategies are necessary to overcome this challenge.
• High Degree of Competition: Intense competition can impact market share and pricing. To stay ahead, CDOs must stand out through technology innovation, quality work, and excellent customer service.

The drivers of the biologics contract development market include technological advancements, increasing demand for biologics, supportive regulatory environments, reduced operational costs, and increased R&D investment. However, challenges such as regulatory hurdles, high development costs, and fierce competition must be overcome for successful market participation. Balancing these drivers and challenges is key to achieving growth and innovation in the industry.

List of Biologics Contract Development Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies biologics contract development companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the biologics contract development companies profiled in this report include-

• WuXi Biologics
• Abzena
• Fujifilm Diosynth Biotechnologies
• KBI Biopharma
• AGC Biologics
• Thermo Fisher Scientific
• Curia Global
• GenScript
• Bionova Scientific
• BioXcellence

Biologics Contract Development by Segment

The study includes a forecast for the global biologics contract development by source, product service, disease indication, and region.

Biologics Contract Development Market by Source [Analysis by Value from 2018 to 2030]:

• Microbial
• Mammalian
• Others

Biologics Contract Development Market by Product Service [Analysis by Value from 2018 to 2030]:

• Cell Line Development
• Process Development
• Others

Biologics Contract Development Market by Disease Indication [Analysis by Value from 2018 to 2030]:

• Oncology
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Others

Biologics Contract Development Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Biologics Contract Development Market

The biologics contract development market is shaped by advancements in technology, investment policies, and increasing demand for biologics. Countries like the United States, China, Germany, India, and Japan are actively participating in these developments and transforming the industry through innovation and investment.

• United States: In the U.S., the biologics contract development market is showing healthy growth due to rising investments in advanced manufacturing technologies and synergies between biotechnology companies and contract development organizations (CDOs)/contract manufacturing organizations (CMOs). Increasing process efficiencies and implementing new technologies like continuous manufacturing and cell/gene therapy remain priorities. Moreover, the U.S. regulatory framework continues to encourage innovation, especially in the approval of biologics.
• China: China is rapidly expanding its biologics contract development capabilities due to state policies supporting biotechnology and pharmaceutical innovation. Recent developments include new biomanufacturing plants and additional resources to improve the scaling up of biologics. China is positioning itself as a leader in global biologics development with significant investment in R&D and international collaboration.
• Germany: Germany is a leader in biologics contract development and production in Europe, supported by favorable policies and regulations. Recent changes include innovations in bioprocessing and increased capacity for high-throughput screening and analysis. As a member of the European Union, Germany benefits from transnational research cooperation and a broad market for biologics.
• India: India's biologics contract development market is growing due to improved infrastructure and increased biopharmaceutical capabilities. Modern factories and updated laws are facilitating quicker approvals. India's low-cost manufacturing and experienced labor are attracting offshore clients seeking cost-effective biologics development solutions.
• Japan: Japan is advancing its biologics contract development through technological innovations and industry collaboration. Recent developments include enhancements in biomanufacturing processes and the integration of cutting-edge technologies like artificial intelligence in drug development. Japan's supportive regulatory structure continues to drive growth and foster international partnerships.

Features of the Global Biologics Contract Development Market

Market Size Estimates: Biologics contract development market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Biologics contract development market size by source, product service, disease indication, and region in terms of value ($B).

Regional Analysis: Biologics contract development market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different sources, product services, disease indication, and regions for the biologics contract development market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the biologics contract development market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the biologics contract development market by source (microbial, mammalian, and others), product service (cell line development, process development, and others), disease indication (oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Biologics Contract Development Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Biologics Contract Development Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Biologics Contract Development Market by Source
  • 3.3.1: Microbial
  • 3.3.2: Mammalian
  • 3.3.3: Others
• 3.4: Global Biologics Contract Development Market by Product Service
  • 3.4.1: Cell Line Development
  • 3.4.2: Process Development
  • 3.4.3: Others
• 3.5: Global Biologics Contract Development Market by Disease Indication
  • 3.5.1: Oncology
  • 3.5.2: Immunological Disorders
  • 3.5.3: Cardiovascular Disorders
  • 3.5.4: Hematological Disorders
  • 3.5.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Biologics Contract Development Market by Region
• 4.2: North American Biologics Contract Development Market
  • 4.2.1: North American Biologics Contract Development Market by Source: Microbial, Mammalian, and Others
  • 4.2.2: North American Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others
• 4.3: European Biologics Contract Development Market
  • 4.3.1: European Biologics Contract Development Market by Source: Microbial, Mammalian, and Others
  • 4.3.2: European Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others
• 4.4: APAC Biologics Contract Development Market
  • 4.4.1: APAC Biologics Contract Development Market by Source: Microbial, Mammalian, and Others
  • 4.4.2: APAC Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others
• 4.5: ROW Biologics Contract Development Market
  • 4.5.1: ROW Biologics Contract Development Market by Source: Microbial, Mammalian, and Others
  • 4.5.2: ROW Biologics Contract Development Market by Disease Indication: Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Biologics Contract Development Market by Source
  • 6.1.2: Growth Opportunities for the Global Biologics Contract Development Market by Product Service
  • 6.1.3: Growth Opportunities for the Global Biologics Contract Development Market by Disease Indication
  • 6.1.4: Growth Opportunities for the Global Biologics Contract Development Market by Region
• 6.2: Emerging Trends in the Global Biologics Contract Development Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Biologics Contract Development Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Biologics Contract Development Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: WuXi Biologics
• 7.2: Abzena
• 7.3: Fujifilm Diosynth Biotechnologies
• 7.4: KBI Biopharma
• 7.5: AGC Biologics
• 7.6: Thermo Fisher Scientific
• 7.7: Curia Global
• 7.8: GenScript
• 7.9: Bionova Scientific
• 7.10: BioXcellence